Condition: Pompe Disease (Late-onset) · Pompe Disease Late-Onset · LOPD · Sponsor: AskBio Inc
This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of AB-1009 in adult participants with late-onset Pompe disease (LOPD).
This description comes directly from the study's public registry record.
AskFirst Patient Engagement · 919-561-6210 · AskFirst@AskBio.com
Always discuss trial participation with your own doctor first.
| Barrow Neurological Institute | Phoenix, Arizona, United States | Not Yet Recruiting |
| University of California, Irvine (UCI) | Irvine, California, United States | Recruiting |
| Stanford Neuroscience Health Center | Palo Alto, California, United States | Not Yet Recruiting |
| NYU Langone | New York, New York, United States | Not Yet Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Pittsburgh Medical Center (UPMC) | Pittsburgh, Pennsylvania, United States | Not Yet Recruiting |
| University of Texas Southwest Medical Center | Dallas, Texas, United States | Recruiting |
| Virginia Commonwealth University (VCU) | Richmond, Virginia, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07282847